Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)-Reference-Cited by-同舟云学术

Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)

Published:2016-10 Issue:10 Volume:27 Page:1873-1878
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Mavroudis D.,Matikas A.,Malamos N.,Papakotoulas P.,Kakolyris S.,Boukovinas I.,Athanasiadis A.,Kentepozidis N.,Ziras N.,Katsaounis P.,Saloustros E.,Georgoulias V.

Funder

Hellenic Oncology Research Group

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/10/1873/16698221/mdw274.pdf

Reference16 articles.

1. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomized trials;Peto;Lancet,2012

2. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer;Poole;N Engl J Med,2006

3. Weekly paclitaxel in the adjuvant treatment of breast cancer;Sparano;N Engl J Med,2008